Sökning: onr:"swepub:oai:DiVA.org:umu-178239" >
Longitudinal change...
-
Bouzina, HabibLund University,Lunds universitet,Lund Hemodynamic Lab,Forskargrupper vid Lunds universitet,Lund University Research Groups,Skåne University Hospital,Lund Univ, Sweden
(författare)
Longitudinal changes in risk status in pulmonary arterial hypertension
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
2020-12-10
-
John Wiley & Sons,2021
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-178239
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-178239URI
-
https://doi.org/10.1002/ehf2.13162DOI
-
https://lup.lub.lu.se/record/1a6358bc-1789-4831-9ff1-5c0155113529URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:145327437URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-172237URI
-
https://gup.ub.gu.se/publication/299247URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Swedish Association of Local Authorities and Regions; Merck & Co., Inc. Kenilworth, NJ, USA; Bayer AG, Berlin, Germany
-
Aims: Low‐risk status in pulmonary arterial hypertension (PAH) predicts better survival. The present study aimed to describe changes in risk status and treatment approaches over multiple clinical assessments in PAH, taking age and comorbidity burden into consideration.Methods and results: The study included incident patients from the Swedish PAH registry, diagnosed with PAH in 2008–2019. Group A (n = 340) were ≤75 years old with <3 comorbidities. Group B (n = 163) were >75 years old with ≥3 comorbidities. Assessments occurred at baseline, first‐year (Y1) and third‐year (Y3) follow‐ups. The study used an explorative and descriptive approach. Group A: median age was 65 years, 70% were female, and 46% had no comorbidities at baseline. Baseline risk assessment yielded low (23%), intermediate (66%), and high risk (11%). Among patients at low, intermediate, or high risk at baseline, 51%, 18%, and 13%, respectively, were at low risk at Y3. At baseline, monotherapy was the most common therapy among low (68%) and intermediate groups (60%), while dual therapy was the most common among high risk (69%). In patients assessed as low, intermediate, or high risk at Y1, 66%, 12%, and 0% were at low risk at Y3, respectively. Of patients at intermediate or high risk at Y1, 35% received monotherapy and 13% received triple therapy. In low‐risk patients at Y1, monotherapy (40%) and dual therapy (43%) were evenly distributed. Group B: median age was 77 years, 50% were female, and 44% had ≥3 comorbidities at baseline. At baseline, 8% were at low, 80% at intermediate, and 12% at high risk. Monotherapy was the most common therapy (62%) in Group B at baseline. Few patients maintained or reached low risk at follow‐ups.Conclusions: Most patients with PAH did not meet low‐risk criteria during the 3 year follow‐up. The first year from diagnosis seems important in defining the longitudinal risk status.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Rådegran, GöranLund University,Lunds universitet,Lund Hemodynamic Lab,Forskargrupper vid Lunds universitet,Lund University Research Groups,Skåne University Hospital,Lund Univ, Sweden(Swepub:lu)med-grd
(författare)
-
Butler, OisinBayer Pharma AG,Bayer AG, Germany
(författare)
-
Hesselstrand, RogerLund University,Lunds universitet,Hjärt-lungsjukdom - information, stöd och bemötande,Forskargrupper vid Lunds universitet,Forskargruppen för systemisk skleros, Lund,Cardiopulmonary disease - information, support and reception,Lund University Research Groups,Lund Systemic Sclerosis Research Group,Skåne University Hospital,Lund Univ, Sweden(Swepub:lu)reum-rhe
(författare)
-
Hjalmarsson, Clara,1969Gothenburg University,Göteborgs universitet,University of Gothenburg,Sahlgrenska University Hospital,Gothenburg Univ, Sweden,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xhjacl
(författare)
-
Holl, KatsiarynaBayer Pharma AG,Bayer AG, Germany
(författare)
-
Jansson, KjellLinköpings universitet,Linköping University,Medicinska fakulteten,Avdelningen för diagnostik och specialistmedicin,Region Östergötland, Fysiologiska kliniken US,Region Östergötland, Kardiologiska kliniken US(Swepub:liu)kjeja02
(författare)
-
Klok, RogierMerck Sharp And Dohme Corp., US
(författare)
-
Söderberg, StefanUmeå University,Umeå universitet,Avdelningen för medicin,Umea Univ, Sweden(Swepub:umu)stso0001
(författare)
-
Kjellström, BarbroKarolinska Institutet,Karolinska Institute,Lund University,Lunds universitet,Klinisk fysiologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Clinical Physiology (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Karolinska Inst, Sweden(Swepub:lu)ba8516kj
(författare)
-
Lund Hemodynamic LabForskargrupper vid Lunds universitet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:ESC Heart Failure: John Wiley & Sons8:1, s. 680-6902055-5822
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bouzina, Habib
-
Rådegran, Göran
-
Butler, Oisin
-
Hesselstrand, Ro ...
-
Hjalmarsson, Cla ...
-
Holl, Katsiaryna
-
visa fler...
-
Jansson, Kjell
-
Klok, Rogier
-
Söderberg, Stefa ...
-
Kjellström, Barb ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
ESC Heart Failur ...
- Av lärosätet
-
Umeå universitet
-
Lunds universitet
-
Karolinska Institutet
-
Linköpings universitet
-
Göteborgs universitet